Merck & Co., Inc. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
Merck & Co., Inc. (MRK) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax of $297.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax · last filed 2020-02-26
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2015-06-30 was -$176.00M.
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2015-03-31 was $252.00M.
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2014-12-31 was $249.00M, a 315.00% increase year-over-year.
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2014-09-30 was $254.00M.
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2018 was $297.00M.
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2017 was -$446.00M.
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2016 was -$66.00M.
- Merck & Co., Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2015 was -$126.00M, a 131.66% decline from fiscal 2014.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 12 month |
|---|---|---|---|---|
| 2018-12-31 | $297.00M 10-K · filed 2019-02-27 | |||
| 2017-12-31 | -$446.00M 10-K · filed 2020-02-26 | |||
| 2016-12-31 | -$66.00M 10-K · filed 2019-02-27 | |||
| 2015-12-31 | -$126.00M 10-K · filed 2018-02-27 | |||
| 2015-06-30 | -$176.00M 10-Q · filed 2015-08-06 | $76.00M 10-Q · filed 2015-08-06 | $325.00M derived: sum of 3 quarters · filed 2017-02-28 | $579.00M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $252.00M 10-Q · filed 2015-05-07 | $501.00M derived: sum of 2 quarters · filed 2017-02-28 | $755.00M derived: sum of 3 quarters · filed 2017-02-28 | $716.00M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $249.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $503.00M derived: sum of 2 quarters · filed 2017-02-28 | $464.00M derived: sum of 3 quarters · filed 2017-02-28 | $398.00M 10-K · filed 2017-02-28 |
| 2014-09-30 | $254.00M 10-Q · filed 2014-11-10 | $215.00M derived: sum of 2 quarters · filed 2015-08-06 | $149.00M 10-Q · filed 2014-11-10 | $209.00M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | -$39.00M 10-Q · filed 2015-08-06 | -$105.00M 10-Q · filed 2015-08-06 | -$45.00M derived: sum of 3 quarters · filed 2016-02-26 | -$147.00M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | -$66.00M 10-Q · filed 2015-05-07 | -$6.00M derived: sum of 2 quarters · filed 2016-02-26 | -$108.00M derived: sum of 3 quarters · filed 2016-02-26 | -$73.00M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | $60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$42.00M derived: sum of 2 quarters · filed 2016-02-26 | -$7.00M derived: sum of 3 quarters · filed 2016-02-26 | $229.00M 10-K · filed 2016-02-26 |
| 2013-09-30 | -$102.00M 10-Q · filed 2014-11-10 | -$67.00M derived: sum of 2 quarters · filed 2014-11-10 | $169.00M 10-Q · filed 2014-11-10 | $167.00M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $35.00M 10-Q · filed 2014-08-07 | $271.00M 10-Q · filed 2014-08-07 | $269.00M derived: sum of 3 quarters · filed 2015-02-27 | $126.00M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | $236.00M 10-Q · filed 2014-05-08 | $234.00M derived: sum of 2 quarters · filed 2015-02-27 | $91.00M derived: sum of 3 quarters · filed 2015-02-27 | $193.00M derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | -$145.00M derived: sum of 2 quarters · filed 2015-02-27 | -$43.00M derived: sum of 3 quarters · filed 2015-02-27 | -$101.00M 10-K · filed 2015-02-27 |
| 2012-09-30 | -$143.00M 10-Q · filed 2013-11-07 | -$41.00M derived: sum of 2 quarters · filed 2013-11-07 | -$99.00M 10-Q · filed 2013-11-07 | -$59.00M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $102.00M 10-Q · filed 2013-08-07 | $44.00M 10-Q · filed 2013-08-07 | $84.00M derived: sum of 3 quarters · filed 2014-02-27 | $144.00M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | -$58.00M 10-Q · filed 2013-05-09 | -$18.00M derived: sum of 2 quarters · filed 2014-02-27 | $42.00M derived: sum of 3 quarters · filed 2014-02-27 | $12.00M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $100.00M derived: sum of 2 quarters · filed 2014-02-27 | $70.00M derived: sum of 3 quarters · filed 2014-02-27 | -$37.00M 10-K · filed 2014-02-27 |
| 2011-09-30 | $60.00M 10-Q · filed 2012-11-09 | $30.00M derived: sum of 2 quarters · filed 2012-11-09 | -$77.00M 10-Q · filed 2012-11-09 | |
| 2011-06-30 | -$30.00M 10-Q · filed 2012-08-07 | -$137.00M 10-Q · filed 2012-08-07 | ||
| 2010-12-31 | $83.00M 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |